Patents Assigned to Sopherion Therapeutics, Inc.
  • Anti-angiogenic peptides and methods of use thereof
    Publication number: 20090047335
    Abstract: Anti-angiogenic peptides that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR). Such peptides may also be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases and skin disorders.
    Type: Application
    Filed: August 5, 2005
    Publication date: February 19, 2009
    Applicant: SOPHERION THERAPEUTICS, INC.
    Inventors: Luca Rastelli, Mary Kay Lescoe, Melissa Corso, Richard Kitson, Judith Landin, Lina Souan, Uriel M. Malyankar
  • Anti-Angiogenic Peptides and Methods of Use Thereof
    Publication number: 20080207502
    Abstract: Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides maybe used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF, or integrin activation of endothelial cells in angiogenesis-associated diseases such as cancer, leukemia, multiple myeloma, inflammatory diseases, eye diseases and skin disorders.
    Type: Application
    Filed: October 14, 2005
    Publication date: August 28, 2008
    Applicant: SOPHERION THERAPEUTICS, INC.
    Inventors: Luca Rastelli, Judith Landin, Uriel Malyankar, Richard Kitson, Melissa Corso, Kenneth Brunson
  • Method to screen ligands using eukaryotic cell display
    Publication number: 20030235864
    Abstract: Methods and compositions for the screening and identification of ligands that are expressed and displayed on the outer surface of eukaryotic cells and screening for binding of the ligand to a receptor domain of a chimeric fusion receptor protein which is also expressed and displayed on the surface of the cells have been developed. Binding to the receptor domain activates, inhibits, or modulates the enzymatic function of the receptor intracellular domain of the fusion protein.
    Type: Application
    Filed: June 5, 2003
    Publication date: December 25, 2003
    Applicant: Sopherion Therapeutics, Inc.
    Inventor: Samy Ashkar